Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: European journal of haematology, 114, 1, S. 17-25
- Ereignis
-
Veröffentlichung
- (wo)
-
Bochum
- (wer)
-
Ruhr-Universität Bochum
- (wann)
-
2024
- Urheber
-
Wille, Kai
Dumke, Marvin
Wilsdorf, Nadine
Sadjadian, Parvis
Schneider, Artur
Jender-Bartling, Stephanie
Kolatzki, Vera
Horstmann, Anette
Meixner, Raphael
Jiménez-Muñoz, Marina
Fuchs, Christiane
Tischler, Hans-Joachim
Griesshammer, Martin
- URN
-
urn:nbn:de:hbz:294-114969
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wille, Kai
- Dumke, Marvin
- Wilsdorf, Nadine
- Sadjadian, Parvis
- Schneider, Artur
- Jender-Bartling, Stephanie
- Kolatzki, Vera
- Horstmann, Anette
- Meixner, Raphael
- Jiménez-Muñoz, Marina
- Fuchs, Christiane
- Tischler, Hans-Joachim
- Griesshammer, Martin
- Ruhr-Universität Bochum
Entstanden
- 2024
Ähnliche Objekte (12)
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis